JP2008247874A - Hair growth stimulant - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a hair growth stimulant excellent in hair growth effect and contains a tetrapeptide Met-Ile-Thr-Leu derived from soybean β-conglycinin(e) α'subunit or a tetrapeptide Met-Ile-Ile-Ile derived from glycinin(e). <P>SOLUTION: The hair growth stimulant contains, as an effective component, a tetrapeptide Met-Ile-Thr-Leu derived from soybean β-conglycinin α'subunit or a tetrapeptide Met-Ile-Ile-Ile derived from glycinin. <P>COPYRIGHT: (C)2009,JPO&INPIT

Description

  The present invention relates to a hair growth-promoting agent, and more specifically, hair growth containing a tetrapeptide Met-Ile-Thr-Leu derived from soybean β-conglycinin α ′ subunit or a glycinin-derived tetrapeptide Met-Ile-Ile-Ile as an active ingredient. Relates to accelerators.

  Many people suffer from alopecia due to aging, genetic predisposition, social stress, etc., and various hair growth agents that promote hair growth and anti-hair loss agents that prevent hair loss have been developed.

  For example, an anti-hair removal agent containing a peptide derived from soybean protein having a specific sequence as an active ingredient is known (see, for example, Patent Document 1). Patent Document 1 shows that a soybean protein-derived peptide, which has not been known to have an anti-hair removal agent at all, significantly suppresses the progression of alopecia, particularly alopecia associated with the use of an anticancer agent. Has been. Alopecia due to administration of an anticancer agent is caused by cell death (apoptosis) of the hair matrix cells that produce hair by the anticancer agent, and the anti-hair loss agent is a substance that can suppress such cell death. On the other hand, a hair growth-promoting substance is a substance that promotes the growth of hair matrix cells and keratinocytes by activating hair papilla cells that function to regulate the growth of hair matrix cells. It is completely different from the agent. Therefore, cited document 1 about an anti-hair removal agent does not describe or suggest the hair-growth effect.

  Moreover, the hair restorer which contains a specific peptide as an active ingredient is known (for example, refer patent document 2). However, with the peptide used in Patent Document 2, the administration form is also by oral administration, and in particular, transdermal administration did not show sufficient effects.

  Therefore, the tetrapeptide Met-Ile-Thr-Leu derived from soybean β-conglycinin α ′ subunit used in the present invention or the tetrapeptide Met-Ile-Ile-Ile derived from glycinin is a substance already known. The hair growth promoting effect was not known at all.

JP-A-9-249535 International Publication No. 00/29425 Pamphlet

  The object of the present invention is to improve hair growth, which contains the tetrapeptide Met-Ile-Thr-Leu derived from soybean β-conglycinin α ′ subunit or the tetrapeptide Met-Ile-Ile-Ile derived from soybean β-conglycinin as an active ingredient. It is to provide an accelerator.

  That is, the present invention relates to a hair growth-promoting agent comprising a tetrapeptide Met-Ile-Thr-Leu derived from soybean β-conglycinin α ′ subunit or a glycinin-derived tetrapeptide Met-Ile-Ile-Ile as an active ingredient.

  It is preferably for transdermal administration.

  The present invention obtains an excellent effect of promoting hair growth by containing, as an active ingredient, a tetrapeptide Met-Ile-Thr-Leu derived from soybean β-conglycinin α ′ subunit or a tetrapeptide Met-Ile-Ile-Ile derived from glycinin. be able to.

  The present invention relates to a hair growth-promoting agent comprising a tetrapeptide Met-Ile-Thr-Leu derived from soybean β-conglycinin α ′ subunit or a tetrapeptide Met-Ile-Ile-Ile derived from glycinin as an active ingredient.

  Met-Ile-Thr-Leu (hereinafter referred to as MITL) and Met-Ile-Ile-Ile (hereinafter referred to as MIII) used in the present invention are tetrapeptides derived from soybean β-conglycinin α ′ subunit, respectively. And a glycinin-derived tetrapeptide.

  MITL has previously decomposed soybean β-conglycinin α ′ subunit with subtilisin and then hydrolyzed with trypsin. It can be obtained by fractionation by chromatography (HPLC). Here, subtilisin is an enzyme of microbial origin and is not present in the human body. Therefore, for example, even if soy protein is orally administered to humans as it is, the soy protein is not decomposed into MITL, so that no hair-growth action can be obtained. That is, MITL can be obtained only by decomposing using both subtilisin and trypsin.

  MIII can be obtained by decomposing and fractionating glycinin in the same manner as MITL.

  The hair growth-promoting agent of the present invention is a tetrapeptide Met-Ile-Thr-Leu derived from soybean β-conglycinin α ′ subunit or a glycinin-derived tetrapeptide Met-Ile- that has not been known to have a hair growth promoting effect until now. By including Ile-Ile as an active ingredient, an excellent hair-growth promoting effect can be obtained.

  Hair is produced by hair cells that repeat cell division by the action of various growth factors secreted from hair papilla cells and keratinize by the presence of keratinocytes (keratinocytes). Hair growth promotion is to promote the hair growth action by activating the hair papilla cells or growing hair matrix cells or keratinocytes.

  The hair growth promoter of the present invention has an excellent keratinocyte proliferation effect by including a specific peptide. The dose necessary for obtaining the effect as a hair growth promoter varies depending on the type of the target disease, the sex, age, weight, symptom, or administration form of the patient and is not particularly limited, but in general, MITL, MIII The amount is preferably 10 to 1,000 mg / person per day, and is used once or several times. This dose is less than that used when used as an anti-hair loss agent, and the required amount may be about 1/30 that of an anti-hair loss agent. Inhibition of hair loss by anticancer drugs requires suppression of apoptosis of hair matrix cells by anticancer drugs, whereas hair growth promoting action is the promotion of the transition from the resting phase to the growth phase in the hair cycle. This is because of a completely different mechanism.

  The hair growth promoter of the present invention can be administered orally or parenterally. Oral administration agents can be solid preparations such as powders, granules, capsules and tablets, or liquid preparations such as syrups and elixirs. Moreover, as a parenteral administration agent, it can be set as a coating agent, an injection, a suppository, etc. These preparations are produced according to a conventional method by adding a pharmacologically and pharmaceutically acceptable production aid to the active ingredient. Among these, when given systemically by oral administration, etc., there is a possibility of showing hair growth promoting action on body hair etc., whereas in the case of transdermal administration, the effect limited to the site where hair growth is desired to be promoted Therefore, it is preferably used as a transdermal agent, and more preferably used as a coating agent such as an external preparation for skin.

  When using this manufacturing adjuvant, it is preferable that the content is 0.1 to 10 weight% in the hair growth promoter of this invention, and it is more preferable that it is 0.3 to 1 weight%. Outside this range, the hair-growth effect of the present invention tends to be insufficient.

  When producing solid preparations for oral administration, the active ingredients MITL and MIII are mixed with excipients to form powders, or if necessary, binders, disintegrants, etc. are added and wet. Alternatively, it can be granulated dry.

  Examples of the excipient include lactose, starch, crystalline cellulose, lactose calcium, and anhydrous silicic acid. Examples of the binder include sucrose, hydroxypropyl cellulose, and polyvinylpyrrolidone. Examples of the disintegrant include carboxy. Examples thereof include methyl cellulose and carboxymethyl cellulose calcium.

  In order to produce a tablet, these powders and granules may be tableted as they are or with a lubricant added. These granules or tablets can be coated with an enteric base and enteric preparations, or coated with ethyl cellulose, carnauba wax, hydrogenated oil, etc. to form a sustained preparation. To produce capsules, powders or granules are filled into hard capsules, or active ingredients are dissolved as they are or dissolved in glycerin, polyethylene glycol, sesame oil, olive oil, etc., and then coated with a gelatin film to form soft capsules. be able to.

  Examples of the lubricant include magnesium stearate and talc, and examples of the enteric base include hydroxypropyl methylcellulose phthalate and methacrylic acid-methyl methacrylate copolymer.

  In order to produce a liquid preparation for oral administration, an active ingredient and a sweetener such as sucrose, sorbitol, and glycerin are dissolved in water to add a transparent syrup, further essential oil, ethanol, etc. to make an elixir, Gum arabic, tragacanth, polysorbate 80, sodium carboxymethyl cellulose and the like may be added to form an emulsion or suspension. These liquid preparations may contain a flavoring agent, a coloring agent, a preservative and the like as desired.

  In order to produce an injection, the active ingredient is optionally adjusted to pH adjusting agents such as hydrochloric acid, sodium hydroxide, lactose, lactic acid, sodium, sodium phosphate-hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, glucose, etc. Dissolve in distilled water for injection together with an isotonic agent, filter aseptically and fill into ampoules, or add mannitol, dextrin, cyclodextrin, gelatin, etc. Good. Further, lecithin, polysorbate 80, polyoxyethylene hydrogenated castor oil and the like can be added to the active ingredient and emulsified in water to give an emulsion for injection.

  To produce a rectal dosage form, the active ingredient is moistened and dissolved together with a suppository base such as cacao butter, fatty acid tri-, di- and monoglycerides, polyethylene glycol, etc., poured into a mold and cooled, or the active ingredient is made of polyethylene. After dissolving in glycol, soybean oil, etc., it may be covered with a gelatin film.

  In order to produce a coating agent such as an external preparation for skin, the active ingredient is added to white petrolatum, beeswax, liquid paraffin, polyethylene glycol, etc., and if necessary, moistened and kneaded to make an ointment, or rosin, acrylic acid After kneading with an adhesive such as an alkyl ester polymer, it can be spread on a nonwoven fabric such as polyethylene to obtain a tape agent.

  Next, the present invention will be described with reference to examples, but the present invention is not limited to these examples. In the examples, “parts” and “%” are based on weight unless otherwise specified.

Example 1 (Keratinocyte proliferation promoting action)
A 4-day-old C3H / HeN mouse was used as a specimen. The skin on the back of this specimen was collected to obtain keratinocytes. To the obtained keratinocytes, an aqueous solution of MITL was added at the concentration shown in Table 1, cultured for 4 days, the number of keratinocytes was counted, and the keratinocyte proliferation promotion rate was calculated according to the following formula from the number of cells without addition of the peptide and after addition culture. Asked. The evaluation results are shown in Table 1 and FIG.
(Keratinocyte growth promotion rate (%)) =
(Number of keratinocytes after culture with addition of peptide) / (Number of keratinocytes after culture without addition of peptide) × 100

Example 2 (Keratinocyte proliferation promoting action)
The keratinocyte proliferation promotion rate was evaluated in the same manner as in Example 1 except that MIII was used as a peptide. The evaluation results are shown in Table 1 and FIG.

From the results shown in Table 1 and FIG. 1, it was found that MITL and MIII have a keratinocyte proliferation promoting action, and the effects were remarkably confirmed particularly when the concentrations of MITL and MIII were 10 ⁻⁶ to 10 ⁻⁴ M.

Example 3 (hair growth effect)
Seven-day-old C3H / HeN Black mice were used as specimens. The back hair of this specimen was shaved with a clipper and an electric razor, and 3 days later, a 2% solution of MITL (water / ethanol / propylene glycol = 2: 3: 5 solution) was transdermally administered (applied) for 12 to 14 days. . Administration was performed once a day between 2pm and 3pm. The hair growth area ratio was determined by the following formula, and the results are shown in Table 2 and FIG.

The hair growth area is calculated by an image analyzer after taking a picture.
(Hair growth area ratio (%)) = (Area where hair grows) / (Area shaved) × 100

Example 4 (hair growth effect)
The hair growth area ratio was determined in the same manner as in Example 3 except that MIII was used as the peptide. The results are shown in Table 2 and FIG.

Comparative Example 1
The hair growth area ratio was determined in the same manner as in Example 3 except that the peptide was not administered. The results are shown in Table 2 and FIG.

  From the results in Table 2 and FIG. 2, it was found that MITL and MIII have a hair growth promoting action. Moreover, the remarkable hair growth promotion effect was confirmed by the MITL2% solution.

Example 5 (hair growth effect)
The hair-growth area ratio was determined in the same manner as in Example 3 except that the soy protein subtilisin or trypsin digest was used as the enzyme digest. The results are shown in Table 3 and FIG.

Comparative Example 2 (hair growth effect)
The hair growth area ratio was determined in the same manner as in Example 3 except that a trypsin digest of soybean protein was used as the enzyme digest. The results are shown in Table 3 and FIG.

  From the results shown in Table 3 and FIG. 3, in order to produce MITL and MIII from soy protein, two types of proteolytic enzymes derived from microorganisms and from the digestive tract of animals are required, so that soy protein was simply administered. It became clear that it would not be possible to obtain the same effect by itself.

It is a graph which shows the skin keratinocyte proliferation promotion rate at the time of using MITL and MIII of Example 1 and Example 2. It is a graph which shows the hair growth area rate at the time of using MITL and MIII. It is a graph which shows the hair-growth area rate at the time of using the subtilisin (Subtilisin) of soybean protein, a trypsin (Trypsin) digest, and the trypsin (Trypsin) digest of soybean protein.

Claims (2)

A hair growth-promoting agent comprising a tetrapeptide Met-Ile-Thr-Leu derived from soybean β-conglycinin α 'subunit or a glycinin-derived tetrapeptide Met-Ile-Ile-Ile as an active ingredient. The hair growth promoter according to claim 1, which is for transdermal administration.

Images